So far, the biggest collections of drug response protein profiles in ovarian cancer cells cover 1) targeted antibody signal measurements of a total of 210 protein and phosphorylation sites by antibody-based reverse-phase protein array (RPPA) in several ovarian cancer cell lines and 2) a study focused on BET bromodomain inhibition conducted in cell lines using mass spectrometry (Zhao et al. 2020; Gonçalves et al. 2022; Kurimchak et al. 2016). Here, DNER is linked to ovarian cancer.